Related Experiment Video

Updated: Jun 5, 2026

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats
07:31

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats

Published on: December 2, 2016

N-terminal pro-atrial natriuretic peptide reflects cardiac remodelling in stage 1 hypertension

N Partanen1, M Husso, O Vuolteenaho

  • 1Department of Internal Medicine, Kuopio University Hospital and University of Kuopio, Kuopio, Finland.

Journal of Human Hypertension
|January 21, 2011
PubMed

Insights

Early detection of left ventricular hypertrophy (LVH) is crucial for better prognosis. Natriuretic peptides (NPs) like NT-proANP may reflect early cardiac remodeling in hypertension, but do not reliably detect LVH in newly diagnosed patients.

Area of Science:

  • Cardiology
  • Hypertension Research
  • Biomarker Discovery

Background:

  • Early detection of left ventricular hypertrophy (LVH) is vital as treatment-induced regression improves patient prognosis.
  • Hypertension is a significant risk factor for cardiac remodeling, including LVH.
  • Natriuretic peptides (NPs) are investigated as potential biomarkers for cardiac changes.

Purpose of the Study:

  • To investigate the relationship between cardiac remodeling and natriuretic peptides in individuals with stage 1 hypertension.
  • To assess the utility of N-terminal pro-B-type natriuretic peptide (NT-proBNP) and N-terminal pro-atrial natriuretic peptide (NT-proANP) in detecting LVH and early cardiac remodeling.

Main Methods:

  • Studied 175 apparently healthy, middle-aged individuals with stage 1 hypertension, never treated.
  • Utilized magnetic resonance imaging to determine left ventricular and atrial parameters.
  • Measured systolic blood pressure (BP) and plasma levels of NT-proBNP and NT-proANP.

Main Results:

  • Systolic BP correlated with left ventricular mass index (LVMI) and ventricular septum thickness index (IVSI).
  • Neither NT-proBNP nor NT-proANP correlated with BP, LVMI, or IVSI.
  • NT-proANP, but not NT-proBNP, correlated with left atrial area index (LAAI); subjects with LVH had higher LAAI.

Conclusions:

  • NT-proBNP and NT-proANP measurements do not appear to effectively discriminate LVH in newly diagnosed, apparently healthy hypertensive individuals.
  • NT-proANP shows potential in reflecting early cardiac remodeling in hypertensive heart disease, unlike NT-proBNP.
  • Further research may explore NT-proANP's role in monitoring early hypertensive cardiac changes.

More Related Videos

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure07:13

A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure

Published on: April 30, 2020

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Hormonal Regulation of Blood Pressure01:17

Hormonal Regulation of Blood Pressure

Endocrinal or hormonal intervention in the cardiovascular system is predominantly exerted by the catecholamines - epinephrine and norepinephrine, as well as a slew of hormones that interact with renal function to modulate blood volume.
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction while...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...